Clinical Trials Logo

Sarcoma clinical trials

View clinical trials related to Sarcoma.

Filter by:

NCT ID: NCT05881967 Recruiting - Uterine Sarcoma Clinical Trials

Molecular Mechanism Study of Uterine Sarcoma

Start date: March 1, 2023
Phase:
Study type: Observational

The purpose of this project was to use multi-omics technology to screen the key factors for the occurrence and development of uterine sarcoma.

NCT ID: NCT05876715 Recruiting - Clinical trials for Advanced Soft-tissue Sarcoma

LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma

LINNOVATE
Start date: June 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.

NCT ID: NCT05869994 Recruiting - Sarcoma Clinical Trials

Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures

Start date: January 27, 2023
Phase:
Study type: Observational

The objectives of the study is to evaluate the anti-tumor activity of autologous natural killer cells in cultures of cancer cells obtained from patient's own tumor.

NCT ID: NCT05864144 Recruiting - Breast Cancer Clinical Trials

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Start date: May 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

NCT ID: NCT05860374 Recruiting - Breast Cancer Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Start date: March 2, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

NCT ID: NCT05859074 Recruiting - Melanoma Clinical Trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Start date: May 4, 2023
Phase: Phase 1
Study type: Interventional

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

NCT ID: NCT05858710 Recruiting - Clinical trials for Sarcoma, Soft Tissue

Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma

Start date: April 18, 2023
Phase: Phase 1
Study type: Interventional

This study aims to explore a new therapeutic approach for advanced soft tissue sarcoma (STS) by investigating the safety, tolerability, and maximum tolerable dose (MTD) of DPPG2-TSL-DOX combined with regional hyperthermia (RHT) in patients who have been pre-treated with doxorubicin (DOX).

NCT ID: NCT05857969 Recruiting - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Start date: February 22, 2023
Phase:
Study type: Observational

Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.

NCT ID: NCT05851456 Recruiting - Sarcoma Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

Start date: April 10, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory bone and soft tissue tumors.

NCT ID: NCT05840575 Recruiting - Cancer Clinical Trials

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

MyBrain
Start date: March 1, 2022
Phase:
Study type: Observational

The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function. The aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.